Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin

barbara.lempert Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO Québec ...

Synta Announces Positive Overall Survival Results from GALAXY-1 Phase 2b/3 Trial of Ganetespib

mia.burns Synta Announces Positive Overall Survival Results from GALAXY-1 Phase 2b/3 Trial of Ganetespib in Second-Line Non-Small Cell Lung Cancer   – Data presented at ASCO 2013 ...

Bristol-Myers Announces Phase I Data for Nivolumab and Yervoy

mia.burns Bristol-Myers Squibb Announces Phase 1 Results from First Trial Combining Immune Checkpoint Inhibitors, Investigational Agent Nivolumab and Yervoy® (ipilimumab), in Patients ...

New European Phase II Trial to Test Immunovaccine’s DPX-Survivac In Brain Cancer Patients

barbara.lempert –    IMV’s vaccine targets survivin peptides present on most Glioblastoma (Brain Cancer) cells –    Patients to receive DPX-Survivac in combination ...

Idenix Pharmaceuticals Announces Initiation of Phase II All-Oral Combination Study of Samatasvir and Simeprevir

barbara.lempert Idenix Pharmaceuticals Announces Initiation of Phase II All-Oral Combination Study of Samatasvir (IDX719) and Simeprevir  (TMC435) for the Treatment of Hepatitis C ...

Targacept Announces Initiation of Phase 2b Study of TC-5214 in Overactive Bladder

barbara.lempert Winston-Salem, NC—May 29, 2013—Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics ™, today announced ...

Soricimed Biopharma Inc. Announces U.S. Trial Site for Phase I Clinical Trial of New Cancer Drug, SOR-C13

barbara.lempert Toronto, ON, Canada, May 23, 2013 — Soricimed Biopharma Inc., a private clinical stage company developing novel cancer therapeutics and diagnostics, is pleased ...

FDA Recommends Running Phase 2b Trial of Proellex-V in the Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids

barbara.lempert THE WOODLANDS, Texas, May 22, 2013 (GLOBE NEWSWIRE) — Repros Therapeutics Inc.(R) (Nasdaq:RPRX) today announced it has met with the FDA regarding the clinical ...

Merck Stops Development of Phase III Parkinson’s Drug

barbara.lempert Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine WHITEHOUSE STATION, N.J.–(BUSINESS ...

First patient dosed in the Phase I/II study of Umecrine Mood’s candidate drug for premenstrual dysphoric disorder

barbara.lempert STOCKHOLM – May 23, 2013. Umecrine Mood AB announced today that dosing has been initiated in a randomized Phase I/II study of UC1010 for the treatment of patients ...

Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain

barbara.lempert MENLO PARK, Calif., May 23, 2013 /PRNewswire/ — Virobay, Inc. today announced that their development of an oral treatment for pain has reached an important milestone, ...

Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients

barbara.lempert MILFORD, Mass., May 23, 2013 /PRNewswire/ — Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines for the treatment of ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS